Next-generation sequencing (NGS)
A test that reads many genes from one tumour sample to find actionable changes.
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
Purpose of the test
- Find mutations, fusions and gene copy changes in one test.
- Identifying markers that could open up clinical trial options.
Informs decisions
- Categories of targeted therapies that are worth discussing.
- Compliance criteria for molecular marker-based clinical trials.
How the test is done
DNA and RNA from tumor tissue are read with a sequencing platform, then interpreted together with clinical data.
- Sample type
- Tumor tissue block or blood sample (if using a liquid panel)
- Estimated result time
- Generally one to three weeks, may take longer if orthogonal confirmation is needed.
Limitations
- Different panels examine different lists of genes and types of changes.
- Not all of the changes found have available therapy.
- Some findings require confirmation by other methods.
- Results need to be read together with pathological findings and clinical conditions.
Related
Not displayed
TanyaKanker does not display test-cost estimates. Ask the laboratory or facility providing the test for cost details directly.
Sources
- NCI Dictionary of Cancer Terms(lembaga)
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
To check
- Liver Cancer
Subtype
Reason: Memerlukan pemeriksaan
- Colorectal Cancer
Cancer type
Reason: Memerlukan pemeriksaan
- Stomach Cancer
Cancer type
Reason: Memerlukan pemeriksaan
- TCR-T (engineered T-cell receptor therapy)
Treatment category
Reason: Memerlukan pemeriksaan
- Targeted therapy
Treatment category
Reason: Memerlukan pemeriksaan
- ALK
Biomarker
Reason: Diperiksa melalui
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Complete pathway
EGFR after osimertinib
My treatment stopped working. What does the next step depend on?
- EGFR markerStarting point: what is tested and what the marker does not decide by itself.
- EGFR exon 19 deletionA variant that often makes EGFR inhibition relevant to discuss.
- OsimertinibThe drug that most often forms the context for this question.
- Progression after targeted therapyThe decision situation you face, not a disease name.
- Osimertinib resistance guideThe order of questions and steps when treatment stops working.
- NGS (next-generation sequencing)A test that can assess many genes from one sample, including resistance mechanisms.
- EGFR C797SOne resistance mechanism looked for on repeat testing.
- MET amplificationAnother resistance mechanism that can change the direction of discussion.
- EGFR T790MA mechanism where treatment sequence matters.
A structured summary so repeat testing and treatment history are readable.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.